Nakamura Paul A, Tang Shibing, Shimchuk Andy A, Ding Sheng, Reh Thomas A
Department of Biological Structure, University of Washington, School of Medicine, Seattle, Washington, United States.
University of California-San Francisco, UCSF School of Pharmacy, Department of Pharmaceutical Chemistry, San Francisco California, United States.
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6407-6415. doi: 10.1167/iovs.16-20177.
Mutations in rod photoreceptor genes can cause retinitis pigmentosa (RP). Rod gene expression is regulated by the nuclear hormone receptor, Nr2e3. Genetic deletion of Nr2e3 reprograms rods into cells that resemble cone photoreceptors, and might therefore prevent their death from some forms of RP. There are no identified ligands for Nr2e3; however, reverse agonists might mimic the genetic rescue effect and may be therapeutically useful for the treatment of RP.
We screened for small molecule modulators of Nr2e3 using primary retinal cell cultures and characterized the most potent, which we have named photoregulin1 (PR1), in vitro and in vivo. We also tested the ability of PR1 to slow the progression of photoreceptor degeneration in two common mouse models of autosomal dominant RP, the RhoP23H and the Pde6brd1 mutations.
In developing retina, PR1 causes a decrease in rod gene expression and an increase in S opsin+ cones. Photoregulin1 continues to inhibit rod gene expression in adult mice. When applied to two mouse models of RP, PR1 slows the degeneration of photoreceptors.
Chemical compounds identified as modulators of Nr2e3 activity may be useful for the treatment of RP through their effects on expression of disease-causing mutant genes.
视杆光感受器基因的突变可导致视网膜色素变性(RP)。视杆基因的表达受核激素受体Nr2e3调控。Nr2e3基因缺失会将视杆细胞重编程为类似视锥光感受器的细胞,因此可能预防其在某些形式的RP中死亡。目前尚未确定Nr2e3的配体;然而,反向激动剂可能模拟基因拯救效应,对RP的治疗可能具有治疗作用。
我们使用原代视网膜细胞培养物筛选Nr2e3的小分子调节剂,并在体外和体内对最有效的调节剂进行了表征,我们将其命名为光调节蛋白1(PR1)。我们还测试了PR1在常染色体显性RP的两种常见小鼠模型RhoP23H和Pde6brd1突变中减缓光感受器退化进程的能力。
在发育中的视网膜中,PR1导致视杆基因表达减少,S视蛋白阳性视锥细胞增加。光调节蛋白1在成年小鼠中继续抑制视杆基因表达。当应用于两种RP小鼠模型时,PR1减缓了光感受器的退化。
被鉴定为Nr2e3活性调节剂的化合物可能通过影响致病突变基因的表达而对RP的治疗有用。